What is it about?
In this study, we performed the largest genomic exploration of the genetic variation involved in the response to inhaled corticosteroids in pediatric asthma analyzing near 5,000 participants included in the Pharmacogenomics in Childhood Asthma (PiCA) consortium. We found a novel biomarker of the response to inhaled corticosteroids among European-descent participants and revealed that trichostatin A is a potential therapeutical option for asthma treatment.
Featured Image
Photo by Robert Collins on Unsplash
Why is it important?
Inhaled corticosteroids are the most commonly prescribed medication to control asthma symptoms. However, not all individuals treated with this medication achieve adequate control of their symptoms. In children, this non-responsiveness limits their ability to attend school and practice sports and reduce their quality of life. Therefore, it is important to perform studies that identify biomarkers distinguishing those children and young adults that do not respond to inhaled corticosteroids and should be treated with alternative medications.
Read the Original
This page is a summary of: Genome-wide association study of asthma exacerbations despite inhaled corticosteroid use, European Respiratory Journal, December 2020, European Respiratory Society (ERS),
DOI: 10.1183/13993003.03388-2020.
You can read the full text:
Contributors
The following have contributed to this page
